Mumps infection parotitis
Conditions
Interventions
All participants will receive an extra MMR vaccination (intramuscularly) at
visit 1.
Sponsors
RIVM
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy young adult 18-25 years of age., Previously been immunized with two doses of the MMR vaccine according to the Dutch NIP (MMR-1 at ~14 months and MMR-2 at ~9 years).
Exclusion criteria
Exclusion criteria: Medical conditions that will severely affect immunological responses to vaccinations, such as, but not limited to, cancer or an immune disorder., Vaccination should be postponed during any illness with fever >38.5°C until the fever has disappeared., Vaccination with any vaccine during the first two weeks before and four weeks after MMR-3., An additional MMR vaccination during the study., Coagulation disorder and/or anticoagulant medication. , Be or have been under immunosuppressive medical treatment, like cytostatics, high-dose corticosteroids, immune globulins, blood or plasma transfusions that might interfere with the results of the study (within the previous 3 months)., Have or previously had clinical symptoms of mumps virus infection., Have or previously had cases of mumps disease within your Household., Had experienced a previous severe adverse reaction to any vaccine. , Being pregnant; Furthermore, pregnancy should be avoided for 1 month following vaccination. , Breast-feeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| * The mumps-specific VN antibody concentrations (against the vaccine and currently circulating mumps virus strains) and IgG antibody concentrations (including antibody avidity) measured in serum samples taken prior to and 10 days, 4 weeks, 1 year and 3 years following a third vaccine dose of MMR | — |
Secondary
| Measure | Time frame |
|---|---|
| * Frequency and intensity of the local and systemic adverse events * Mumps-specific IgA and IgG (saliva) prior to, 4 weeks and 1 year following a third vaccine dose of MMR * The presence and frequency of mumps-specific memory and effector T- and B-cells in peripheral blood following MMR-3, in a voluntary subset of the participants (n=30) prior to, 4 weeks and 1 year following a third vaccine dose of MMR * Serum IgG response against measles and rubella (components of the MMR vaccine) prior to, 10 days, 4 weeks, 1 year and 3 years following a third vaccine dose of MMR | — |
Countries
Netherlands
Outcome results
None listed